KIMES 2026 Special, Part 2. Following Part 1 on the evolution of energy-based devices, we covered the new growth engines emerging beyond EBD. Clinical interest is no longer confined to energy-based devices alone. How drugs reach the dermis, how energy and drugs are combined in a single procedure, and how the range of available formulations is expanding — delivery, combination, and formulation are increasingly shaping the competitiveness of the overall treatment strategy. Needle-free injectors and needle-based delivery platforms are changing how drugs reach the dermis. A hybrid injector combining drug injection and RF in one device has emerged. And companies are expanding their formulation portfolios beyond exosomes to include biostimulators and HA fillers for the combination-treatment era. We visited four companies — BAZ BIOMEDIC, Curiosis, Huons Meditech, and Primoris International — on the exhibition floor to document this shift firsthand.
#MedicalAestheticNews #KIMES2026 #KMedicalAesthetics #BAZBIOMEDIC #Curiosis #reH #HuonsMeditech #PrimorisInternational
★ Article Link: https://www.aestheticnews.co.kr/news/articleView.html?idxno=11304




Comments
Post a Comment